Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 18/20 | 0.65 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | MC5R | P33032 | 3/20 | 0.53 |
| ▸ | MC3R | P41968 | 3/20 | 0.53 |
| ▸ | MC1R | Q01726 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069651 | 0.91 | MC4R (0.56) | MC4RCNR2BCHEMC5RMC3R | |
| SCHEMBL47149 | 0.90 | MC4R (0.62) | MC4RCNR2BCHEMC5RMC3R | |
| SCHEMBL13124606 | 0.88 | MC4R (0.83) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13124659 | 0.87 | MC4R (0.81) | MC4RMC5RMC3RMC1R | |
| SCHEMBL46851 | 0.85 | MC4R (0.54) | MC4RCNR2BCHEMC5RMC3R | |
| SCHEMBL46875 | 0.85 | MC4R (0.65) | MC4RCNR2BCHEMC5RMC3R | |
| SCHEMBL47195 | 0.82 | MC4R (0.64) | MC4RCNR2BCHEMC5RMC3R | |
| SCHEMBL13124924 | 0.82 | MC4R (0.72) | MC4RCNR2BCHEMC5RMC3R | |
| SCHEMBL47112 | 0.82 | MC4R (0.67) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13124141 | 0.80 | MC4R (0.83) | MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20130165426-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2013-06-27 | — | — | US | disclosed |
| US-20130165426-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2013-06-27 | — | — | US | disclosed |
| US-20130165426-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2013-06-27 | — | — | US | disclosed |
| WO-2012003576-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165426-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC1R | MC4R 1/4885CNR2 136/4885BCHE 4753/4885 |
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC1R | MC4R 1/4885CNR2 119/4885BCHE 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.